Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; Comparison with two established antibodies

Onkologie

Volumn 32, Issue 5, 2009, Pages 238-244

  Dian, Darius ^a,b   Janni, Wolfgang ^a   Kuhn, Christina ^a   Mayr, Doris ^b   Karsten, Uwe ^c   Mylonas, Ioannis ^a   Friese, Klaus ^a   Jeschke, Udo ^a  

^a Department of Obstetrics and Gynecology ^*  (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c GLYCOTOPE GMBH   (Germany)

Author keywords

Breast cancer; Ca15 3; Mucin expression; PankoMab; Prognostic parameters; VU 4 H5

Indexed keywords

CA 15-3 ANTIGEN; DIAGNOSTIC AGENT; EPITOPE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DF3; MONOCLONAL ANTIBODY PANKOMAB; MONOCLONAL ANTIBODY VU 4 H5; MUCIN 1; PARAFFIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; HUMANS; INDICATORS AND REAGENTS; MUCIN-1; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67549118583     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209280     Document Type: Article

References (38)

1. Jeschke U, Karsten U, Wiest I, Schulze S, Kuhn C, Friese K, Walzel H: Binding of galectin-1 (gal-1) to the Thomsen-Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody. Histochem Cell Biol 2006;126:437-444.
2. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I: MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer 2006;5:57.
3. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-15293.
4. Cao Y, Karsten U, Hilgers J: Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues. Tumour Biol 1998;19(suppl 1):88-99.
5. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A: Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003;81:195-207.
6. Garcia MB, Blankenstein MA, van der Wall E, Nortier JW, Schornagel JH, Thijssen JH: Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer. Breast Cancer Res Treat 1990;17:69-76.
7. Ammon A, Eiffert H, Alhusen R, Weber M, Rumelin B, Groh E, Bartsch H, Marschner N, Nagel GA, Krieger G: Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer. Onkologie 1990;13:210-214.
8. Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2007;4:45-60.
9. Ozzello L, De Rosa CM, Blank EW, Cantell K, Ceriani RL, Habif DV, Sr: The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts. Breast Cancer Res Treat 1993;25:265-276.
10. Guddo F, Giatromanolaki A, Koukourakis MI, Reina C, Vignola AM, Chlouverakis G, Hilkens J, Gatter KC, Harris AL, Bonsignore G: MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-671.
11. Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J: A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001;276:6191-6199.
12. Mommers EC, Leonhart AM, von Mensdorff- Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, van Diest PJ: Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int J Cancer 1999;84:466-469.
13. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005;65:10413-10422.
14. Li Y, Bharti A, Chen D, Gong J, Kufe D: Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998;18:7216-7224.
15. Li Y, Kuwahara H, Ren J, Wen G, Kufe D: The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001;276:6061-6064.
16. van de Wiel-van Kemenade, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG: Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151:767-776.
17. Luna-More S, Rius F, Weil B, Jimenez A, Bautista MD, Perez-Mellado A: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 2001;197:419-425.
18. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-1982.
19. van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J: The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007;51:322-335.
20. WHO (2003): World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs; in Tavassoli FA, Devilee P (eds): Tumors of the Breast and Female Genital Organs. Lyon, IARC Press 2007, pp 9-112.
21. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston and I. O. Ellis. Histopathology 1991; 19; 403-410. Histopathology 2002;41:151-153.
22. Non-Operative Diagnosis Subgroup of the National Coordinating Group for Breast Screening Pathology: Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. NHSBP Publication No. 50. Sheffield, NHSBP, 2001.
23. Jeschke U, Richter DU, Hammer A, Briese V, Friese K, Karsten U: Expression of the Thomsen- Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro. Histochem Cell Biol 2002;117:219-226.
24. Jeschke U, Bischof A, Speer R, Briese V, Richter DU, Bergemann C, Mylonas I, Shabani N, Friese K, Karsten U: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors. Anticancer Res 2005;25:1581-1589.
25. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005;25:1719-1723.
26. Hayes DF, Zurawski VR, Jr, Kufe DW: Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-1550.
27. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J: Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, CA, November 17-23, 1996. Tumour Biol 1998;19(suppl1):1-20.
28. Cao Y, Schlag PM, Karsten U: Immunodetection of epithelial mucin (MUC1, MUC3) and mucinassociated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 1997;431:159-166.
29. Croce MV, Colussi AG, Price MR, Segal-Eiras A: Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study. Anticancer Res 1997;17:4287-4292.
30. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989;43:1072-1076.
31. Cao Y, Blohm D, Ghadimi BM, Stosiek P, Xing PX, Karsten U: Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation. J Histochem Cytochem 1997;45:1547-1557.
32. Danielczyk A, Stahn R, Faulstich D, Loffler A, Marten A, Karsten U, Goletz S: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55:1337-1347.
33. Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S: Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumorspecific epitope of the epithelial mucin (MUC1). Glycobiology 2004;14:681-692.
34. Karsten U, von Mensdorff-Pouilly S, Goletz S: What makes MUC1 a tumor antigen? Tumour Biol 2005;26:217-220.
35. Li Y, Cozzi PJ: MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets 2007;7:259-271.
36. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ: Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 2000;165:3451-3460.
37. Walsh MD, McGuckin MA, Devine PL, Hohn BG, Wright RG: Expression of MUC2 epithelial mucin in breast carcinoma. J Clin Pathol 1993;46:922-925.
38. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-232.